Core Laboratories Beats Analyst Estimates on EPS
Core Laboratories (NYS: CLB) reported earnings on Oct. 17. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Core Laboratories met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share grew significantly.
Margins increased across the board.
Core Laboratories reported revenue of $245.4 million. The six analysts polled by S&P Capital IQ expected revenue of $243.9 million on the same basis. GAAP reported sales were 6.1% higher than the prior-year quarter's $231.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.13. The 11 earnings estimates compiled by S&P Capital IQ forecast $1.10 per share. GAAP EPS of $1.14 for Q3 were 23% higher than the prior-year quarter's $0.93 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.7%, 170 basis points better than the prior-year quarter. Operating margin was 30.7%, 270 basis points better than the prior-year quarter. Net margin was 22.2%, 280 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $245.6 million. On the bottom line, the average EPS estimate is $1.13.
Next year's average estimate for revenue is $972.5 million. The average EPS estimate is $4.45.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 547 members out of 557 rating the stock outperform, and 10 members rating it underperform. Among 115 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 113 give Core Laboratories a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Core Laboratories is hold, with an average price target of $127.71.
Are you missing a big story in the energy space? Read about "One Stock to Own Before Nat Gas Act 2011 Becomes Law." Click here for instant access to this free report.
- Add Core Laboratories to My Watchlist.
The article Core Laboratories Beats Analyst Estimates on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.